Prepping for a techbio future, Nvidia invests in another AI drug discovery play

Only hindsight will tell if the current techbio buzz reflects too much — or not enough — hype about the prospects of artificial intelligence and machine learning to reshape drug discovery. Either way, the momentum is bringing new players to the biotech industry. Among them is AI and GPU technology giant Nvidia, which has taken increasing interest in the space.

The announcement Tuesday that Nvidia Corp. (NASDAQ:NVDA) had invested in newly launched EvolutionaryScale marked at least the eleventh biotech in which the tech company has made a direct investment in the past 18 months. ...